HAART is Cost Effective, Lowers Other Health Care Expenses, Study Says
- "Distribution of Health Care Expenditures for HIV-Infected Patients," Clinical Infectious Diseases: Dr. Michael Saag and colleagues at the University of Alabama-Birmingham examined annual health care expenses for 635 HIV-positive people and found that highly active antiretroviral therapy is cost effective despite high costs -- about $10,000 to $15,000 annually -- to the patient. The study finds that HAART decreased the overall cost of health care for HIV-positive people, which also could include non-HAART medications, hospitalization and outpatient clinic visits (Saag et al., Clinical Infectious Diseases, 4/1).
This is part of the KHN Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.